cancer
Conditions
Interventions
Sponsors
the First affiliated Hospital of SooChow University
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. aged 18 years and more; 2. patients with high-grade glioma (WHO III, IV) diagnosed by pathological; 3. Recurrent paitents treated with Stupp regimen ,Radiotherapy alone or chemoradiotherapy over 3 months after surgery; 4. Measurable lesions on cranial magnetic resonance; 5. ECOG score 0-2 6. Expected lifetime acuity = 3 months; 7. No serious function damageof heart, lung and bone marrow, no bleeding tendency, always no cerebral embolism and cerebral hemorrhage medical history No serious hypertension, etc., no serious postoperative complications (including intracranial hematoma and severe intracranial infection; 8. Subjects received treatment caused other damage has been restored, which accepts nitroso or mitomycin interval >=6 weeks; acceptance of other cytotoxic drugs, radiation or surgery >=4 weeks, and the wound has healed completely; 9. Normal function of major organs should meet the following criteria: (1) the blood routine examination must be in accordance with standard: 1) HB=90 g/L (14 days without blood transfusion); 2) ANC=1.5×10^9/L; 3) PLT=80×10^9/L; (2) the biochemical examination must be in accordance with the following criteria: 1) TBIL=1.5×ULN (higher than the normal limit); 2) ALT and AST=2.5×ULNif has liver metastasis ALT and AST=5×ULN; 3) Serum Cr=1×ULN the endogenous creatinine clearance>50 ml/min (Cockcroft-Gault formula); 10. Women of childbearing age must be enrolled in the 7 days before a pregnancy test (serum or urine) results were negative, and the voluntary during the observation period and after the last administration for Nepalese Apa sheet 8 weeks using appropriate methods of contraception; for men, surgical sterilization should be, or agreed during the observation period and after the last administration for Nepalese Apa sheet 8 weeks using appropriate methods of contraception; 11. signed informed consent, compliance is good and agreed to cooperate with the survival of follow-up.
Exclusion criteria
Exclusion criteria: 1. Pregnant or lactation women; 2. suffering from hypertension, the antihypertensive drug therapy can not be reduced to the normal range (systolic blood pressure> 140 mmHg / diastolic blood pressure> 90 mmHg), with level-I myocardial ischemia or myocardial infarctionwith level-I arrhythmia (including QT interval=440 ms) or cardiac insufficiency; 3. The influence of oral drugs and absorption of a variety of factors (Such as unable to swallow, after resection of gastrointestinal tract, chronic diarrhea and intestinal obstruction); 4. Coagulant function abnormality, was treated with thrombolysis or anticoagulation, with a bleeding tendency or there are clear gastrointestinal bleeding concerns, (such as: there are local active ulcer lesions, defecate occult blood as positive); 5. A period of 4 weeks prior to the start of taking the study drug, =CTCAE 2 pneumorrhagia or =CTCAE 3 other organs bleeding event has occurred; 6. A period of 6 months prior to the start of the study dynamic/enous thromboembolism event has occurred, such as cerebrovascular accident (including transient ischemic attack), deep vein thrombosis and pulmonary embolism, etc; 7. using anticoagulants or vitamin K antagonists such as warfarin, heparin or an analogue thereof; in prothrombin time international normalized ratio (INR) <=1.5 premise, to permit the use of low-dose warfarin (adult, 0.6~1.2 million U, once daily) or low-dose aspirin (=100 mg daily dose); 8. Investigator judgment that may affect the conduct of clinical studies and case studies determined.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| progression free survival; | — |
Countries
China
Contacts
Public ContactHuang Yulun
the First affiliated Hospital of SooChow University
Outcome results
None listed